Effect of Dapagliflozin on Secondary Mitral Regurgitation
Status:
Recruiting
Trial end date:
2024-05-01
Target enrollment:
Participant gender:
Summary
A significant reduction in the incidence of CV death or hospitalization for HF has been
observed in randomized trials investigating the CV benefit of Dapagliflozin. Mechanistic
investigations are required to interpret the positive clinical effects of Dapagliflozin on
heart structure and valvular regurgitation.
Phase:
Phase 3
Details
Lead Sponsor:
October 6 University
Collaborators:
Beni-Suef University National Heart Institute, Egypt